Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.


A cellular protein complex consisting of proteolytic enzymes that degrade endogenous proteins, especially those that are damaged, pathogenic, or no longer of use.

[Alteration of earlier prosome (influenced by protease) : pro(grammed), from the earlier belief that proteasomes played a role in regulating messenger RNA translation + -some.]
References in periodicals archive ?
We are excited to offer patients the first oral proteasome inhibitor as an alternative treatment option for those with multiple myeloma," said Gary Kadlec, president of Diplomat.
Food and Drug Administration (FDA) has approved NINLAROA (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Topics to be discussed include deubiquitinating enzymes as drug targets, novel drug targets in the ubiquitin system, ubiquitin-like modifications, ubiquitin pathways in neurobiology, ubiquitin proteasome system and oncology, and proteasome structure and function.
Let's first take a look at one of the primary underlying causes of skin aging: loss of function of the proteasome.
The multi-center study with MLN9708, an investigational, oral proteasome inhibitor, will be conducted in Europe and North America.
In particular, the new work from the Davies lab showed that production of proteasome and a proteasome regulator (Pa28) is controlled by Nrf2 during oxidative stress.
658) examined whether acute experimental exposure to two different aerosols altered proteasome activity in human white blood cells (WBCs) or red blood cells (RBCs) [The proteasome is an intracellular protein degradation system that has been linked to oxidative stress and inflammation.
The ubiquitin proteasome system in the central nervous system; from physiology to pathology; 2008 update.
mass (kDa)/pl 3217 Proteasome activator complex subunit 3 P61289 29.
The proteins that are to be eliminated at the proteasome are marked for destruction by the addition of a small molecule called ubiquitin to differentiate them from proteins that still are needed and must not be degraded.
Carfilzomib is the second proteasome inhibitor; these drugs work by interrupting a key enzyme cancer cells require to survive and multiply.
VELCADE is the first proteasome inhibitor to receive worldwide regulatory approval for the treatment of multiple myeloma (MM).
Full browser ?